R&D How birth tissue donations are fuelling the cell therapy rev... As the burgeoning field of cell therapy evolves, so do the practices around obtaining the raw biological material needed to create these life-changing treatments.
News GSK pays $1.2bn for liver drug as it culls TIGIT programme GSK decided to abandon a TIGIT-targeted drug for cancer this week, then hatched a plan to replace it with a candidate for liver disease MASH.
Market Access Sponsored Bridging research and clinical guidelines – interactive stra... Medical affairs is evolving. Understanding how to harness real-world data and digital insights is essential.